Evaluation of Sympathetic Skin Response and Its Relationship With Clinical Response to Complex Decongestive Therapy in Patients With Postmastectomy Lymphedema (BCRL-SSR)
This prospective observational single-center study aimed to evaluate sympathetic skin response (SSR) in patients with postmastectomy upper extremity lymphedema and to investigate the relationship between SSR parameters and clinical response to complex decongestive therapy (CDT).
Thirty female patients with breast cancer-related lymphedema and thirty healthy female controls were included in the study. All participants underwent autonomic nervous system assessment using SSR and R-R interval variability measurements and completed the Composite Autonomic Symptom Score-31 (COMPASS-31) questionnaire.
Patients in the lymphedema group received a standardized 3-week CDT program consisting of 15 treatment sessions. Clinical response to treatment was evaluated by calculating changes in lymphedema volume before and after treatment. Quality of life, upper extremity function, pain severity, and neuropathic pain symptoms were assessed using LYMQOL-Arm, QuickDASH, Numeric Rating Scale (NRS), and Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
Studieoversigt
Status
Detaljeret beskrivelse
Breast cancer-related lymphedema is a chronic condition that develops following breast cancer treatment and is traditionally considered to result from impaired lymphatic drainage and fluid accumulation. Recent evidence suggests that autonomic nervous system dysfunction may also contribute to the pathophysiology of lymphedema.
The aim of this prospective observational study was to evaluate sympathetic skin response (SSR), autonomic nervous system functions, and their relationship with clinical response to complex decongestive therapy (CDT) in patients with postmastectomy upper extremity lymphedema.
Thirty female patients aged 18-65 years with unilateral upper extremity lymphedema after breast cancer treatment and thirty healthy female controls were included. All participants underwent electrophysiological autonomic nervous system evaluation using SSR and R-R interval variability measurements. In addition, autonomic symptoms were assessed using the Composite Autonomic Symptom Score-31 (COMPASS-31).
Patients in the lymphedema group received a standardized CDT program for 3 weeks, 5 days per week, totaling 15 sessions. Clinical response to treatment was evaluated using changes in lymphedema volume measurements obtained before and after treatment.
Secondary clinical assessments included quality of life evaluation with LYMQOL-Arm, upper extremity functional assessment with QuickDASH, pain severity assessment using the Numeric Rating Scale (NRS), and neuropathic pain evaluation using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
The study aimed to determine whether autonomic dysfunction is present in breast cancer-related lymphedema and whether baseline SSR parameters are associated with clinical response to CDT.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Ankara
-
Ankara, Ankara, Tyrkiet (Türkiye), 06800
- Gaziler Physical Medicine and Rehabilitation Training and Research Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Healthy Control Inclusion Criteria:
- Female volunteers aged between 18 and 65 years
- No history of breast cancer or lymphedema
- No neurological, metabolic, or systemic disease affecting autonomic nervous system function
Healthy Control Exclusion Criteria:
- History of breast cancer or lymphedema
- Polyneuropathy
- Diabetes mellitus
- Hypothyroidism
- Neurological disease
- Systemic diseases affecting autonomic nervous system function
Patient group;
Inclusion Criteria:
Inclusion Criteria:
- Female patients aged between 18 and 65 years
- Postmastectomy upper extremity lymphedema after breast cancer surgery
- Completion of breast cancer treatment protocols
- International Society of Lymphology (ISL) stage I-II lymphedema
Exclusion Criteria:
- Metastatic breast cancer
- Bilateral breast cancer history
- Bilateral upper extremity lymphedema
- Ongoing chemotherapy or radiotherapy
- Infection or allergic skin lesions on the upper extremities
- Medical conditions causing edema, including decompensated heart, lung, or renal failure
- Peripheral nervous system disease or polyneuropathy
- Chronic endocrine, metabolic, neurological, or systemic diseases affecting autonomic nervous system function, including diabetes mellitus, hypo/hyperthyroidism, uremia, heart failure, cardiac arrhythmia, and uncontrolled hypertension
- Presence of a cardiac pacemaker
- Inability to tolerate electrical stimulation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Lymphedema volume difference and sympathetic skin response (SSR) parameters
Tidsramme: Baseline and after 3 weeks of complex decongestive therapy
|
Upper extremity lymphedema volume difference and sympathetic skin response (SSR) parameters were evaluated before and after complex decongestive therapy.
Limb volume was calculated using circumferential measurements obtained at 4-cm intervals with the truncated cone formula.
SSR recordings were obtained using surface electrodes and median nerve stimulation.
Peak-to-peak amplitude and latency values were analyzed.
|
Baseline and after 3 weeks of complex decongestive therapy
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
R-R interval variability (RRIV)
Tidsramme: Baseline and after 3 weeks of complex decongestive therapy
|
Cardiac autonomic function was evaluated using R-R interval variability measurements during resting and deep breathing conditions.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
COMPASS-31 score
Tidsramme: Baseline and after 3 weeks of complex decongestive therapy
|
Autonomic symptoms were evaluated using the Composite Autonomic Symptom Score-31 questionnaire.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
LYMQOL-Arm score
Tidsramme: Baseline and after 3 weeks of complex decongestive therapy
|
Quality of life related to upper extremity lymphedema was evaluated using the LYMQOL-Arm questionnaire.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
QuickDASH score
Tidsramme: Baseline and after 3 weeks of complex decongestive therapy
|
Upper extremity functional status was assessed using the QuickDASH questionnaire.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
Numeric Rating Scale (NRS)
Tidsramme: Baseline and after 3 weeks of complex decongestive therapy
|
Pain severity was evaluated using the Numeric Rating Scale.
|
Baseline and after 3 weeks of complex decongestive therapy
|
|
Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)
Tidsramme: Baseline and after 3 weeks of complex decongestive therapy
|
Neuropathic pain symptoms were evaluated using the LANSS questionnaire.
|
Baseline and after 3 weeks of complex decongestive therapy
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Postoperative komplikationer
- Patologiske processer
- Neoplasmer efter sted
- Neoplasmer
- Hudsygdomme
- Brystsygdomme
- Lymfesygdomme
- Sygdomme i det autonome nervesystem
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Hemiske og lymfatiske sygdomme
- Brystkræft lymfødem
- Brystneoplasmer
- Lymfødem
- Primære dysautonomier
Andre undersøgelses-id-numre
- BCRL-SSR-2026
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Autonom dysfunktion
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbejdspartnereIkke rekrutterer endnuLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitis | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpanien
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisKina
-
Southern California Institute for Research and...Ikke rekrutterer endnuMASH - Metabolic Dysfunction-Associated Steatohepatitis
-
Nabiqasim Industries (Pvt) LtdRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisPakistan
-
Stimdia Medical, Inc.AfsluttetVentilator-induceret diaphragmatic dysfunction (VIDD)Irland, Tjekkiet
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
Tangram Therapeutics PlcRekrutteringSunde deltagere | MASH - Metabolic Dysfunction-Associated SteatohepatitisDet Forenede Kongerige
-
University of Campania Luigi VanvitelliAfsluttetMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien